Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flumioxazin SCHEMBL7581874 | 0.92 | MEN1 (0.33) | MEN1ALDH1A1KMT2ASMN1; SMN2MAPT | |
| Flumioxazin SCHEMBL7581634 | 0.92 | MEN1 (0.34) | MEN1ALDH1A1KMT2ASMN1; SMN2MAPT | |
| Flumioxazin SCHEMBL7578419 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1KMT2ASMN1; SMN2MAPT | |
| Flumioxazin SCHEMBL7580173 | 0.90 | MAPT (0.34) | MEN1ALDH1A1KMT2ASMN1; SMN2MAPT | |
| Flumioxazin SCHEMBL7589105 | 0.90 | MEN1 (0.32) | MEN1ALDH1A1KMT2ASMN1; SMN2MAPT | |
| Flumioxazin SCHEMBL7586293 | 0.90 | MEN1 (0.33) | MEN1ALDH1A1KMT2ASMN1; SMN2MAPT | |
| Flumioxazin SCHEMBL7590012 | 0.89 | MAPT (0.33) | MEN1ALDH1A1KMT2ASMN1; SMN2MAPT | |
| Flumioxazin SCHEMBL7577049 | 0.87 | THRB (0.49) | GRM7GRM4 | |
| Flumioxazin SCHEMBL7589078 | 0.87 | MEN1 (0.30) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| Flumioxazin SCHEMBL7586656 | 0.87 | MAPT (0.31) | MEN1ALDH1A1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3244742-A1 | HERBICIDAL COMBINATION COMPRISING SAFLUFENACIL AND GLUFOSINATE | BASF SE (DE) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016113334-A1 | HERBICIDAL COMBINATION COMPRISING SAFLUFENACIL AND GLUFOSINATE | BASF SE (DE) | 2016-07-21 | — | — | WO | disclosed |
| US-20020004457-A1 | Herbicidal composition | SYNGENTA PARTICIPATIONS AG (CH) | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004457-A1 | Herbicidal composition | PPOX, ALAD, DDT | MEN1 4274/4885ALDH1A1 812/4885KMT2A 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.